Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Good morning, my name is Mohit Bansal. I'm one of the biopharma analyst here at Wells Fargo.
Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.
Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices
Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences will also be a player in the anti-obesity market. The stock is still trading for a reasonable valuation multiple and in case of a potential recession, pharmaceutical companies are often a good, recession-resilient pick.
Gilead Sciences: Buy This Bargain Before It's Gone
Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the company's HIV franchise amounted to about $4.75 billion in the second quarter, an increase of 9.3% quarter-on-quarter. In addition, on August 14, 2024, the FDA approved Livdelzi in combination with UDCA for the treatment of primary biliary cholangitis.
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.
US FDA approves Gilead's liver disease drug
The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.
Gilead Posts Solid Revenue in Q2
Revenue of $7.0 billion, up 6% excluding Veklury. Non-GAAP diluted EPS of $2.01.
